Familiealbumet og de vanskelige fortellingene

publishedVersio

Jeff Werner 2008. Medelvägens estetik. Sverigebilder i USA

For noen år siden hadde min eldste datter sommerjobb som omviser i Gamle Bergen â et bymuseum som framviser et utsnitt av lokal trearkitektur og tilhørende interiører fra slutten av 1700-tallet og fram til omkring 1930-tallet. Museet har årlig et jevnt tilsig av turister av ulike nasjonaliteter, deriblant mange amerikanere. Og det er som regel dem som står for de mest naive turistblødmene. Fjorårets mest oppsiktsvekkende kom fra en ung amerikaner som etter å ha vandret gjennom de nevnte severdigheter, presterte å stille guiden følgende spørsmål: âBut where do you keep your vikings? Are they in a reservation?

Laparoscopic Adjustable Gastric Banding and Hypoglycemia

Obesity is commonplace, and surgical treatment usually includes Roux-en-Y gastric bypasses (RYGBs). RYGBs have the most documented side effects including vitamin deficiencies, rebound weight gain, and symptomatic hypoglycemia; fewer series exist describing hypoglycemia following other bariatric operations. We reviewed all patients undergoing laparoscopic adjustable gastric banding (LAGB) at our institution between 2008 and 2012. Three patients were identified to have symptomatic hypoglycemia following LAGB. Mean time from surgery was 33 months (range 14–45 months), and mean weight loss was 32.7 kg (range 15.9–43.1 kg). None of the patients had preexisting diabetes. Therefore, symptomatic hypoglycemia should be investigated irrespective of bariatric operation

A Modern Cohort of Duodenal Obstruction Patients: Predictors of Delayed Transition to Full Enteral Nutrition

Background:. A common site for neonatal intestinal obstruction is the duodenum. Delayed establishment of enteral nutritional autonomy continues to challenge surgeons and, since early institution of nutritional support is critical in postoperative newborns, identification of patients likely to require alternative nutritional support may improve their outcomes. Therefore, we aimed to investigate risk factors leading to delayed establishment of full enteral nutrition in these patients. Methods:. 87 patients who were surgically treated for intrinsic duodenal obstructions from 1998 to 2012 were reviewed. Variables were tested as potential risk factors. Median time to full enteral nutrition was estimated using the Kaplan-Meier method. Independent risk factors of delayed transition were identified using the multivariate Cox proportional hazards regression model. Results:. Median time to transition to full enteral nutrition was 12 days (interquartile range: 9–17 days). Multivariate Cox analysis identified three significant risk factors for delayed enteral nutrition: gestational age (GA) ≤ 35 weeks (P < .001), congenital heart disease (CHD) (P = .02), and malrotation (P = .03). Conclusions:. CHD and Prematurity are most commonly associated with delayed transition to full enteral nutrition. Thus, in these patients, supportive nutrition should strongly be considered pending enteral nutritional autonomy

Time-resolved measurements from speckle interferometry

We present time-resolved measurements by speckle interferometry of the light scattered by a liquid medium. Measurements were performed by use of reflectance geometry and are compared with results obtained in the same conditions with a femtosecond laser and a streak camera. The setup was also tested in vivo on the forearm of a human volunteer to demonstrate the potential utility of such a setup for biomedical applications

Still Arctic? — The changing Barents Sea

The Barents Sea is one of the Polar regions where current climate and ecosystem change is most pronounced. Here we review the current state of knowledge of the physical, chemical and biological systems in the Barents Sea. Physical conditions in this area are characterized by large seasonal contrasts between partial sea-ice cover in winter and spring versus predominantly open water in summer and autumn. Observations over recent decades show that surface air and ocean temperatures have increased, sea-ice extent has decreased, ocean stratification has weakened, and water chemistry and ecosystem components have changed, the latter in a direction often described as “Atlantification” or “borealisation,” with a less “Arctic” appearance. Temporal and spatial changes in the Barents Sea have a wider relevance, both in the context of large-scale climatic (air, water mass and sea-ice) transport processes and in comparison to other Arctic regions. These observed changes also have socioeconomic consequences, including for fisheries and other human activities. While several of the ongoing changes are monitored and quantified, observation and knowledge gaps remain, especially for winter months when field observations and sample collections are still sparse. Knowledge of the interplay of physical and biogeochemical drivers and ecosystem responses, including complex feedback processes, needs further development.Still Arctic? — The changing Barents SeapublishedVersio

First results from the L3+C experiment at CERN

The L3+C experiment combines the high-precision spectrometer of the L3 detector at LEP, CERN, with a small air shower array. The momenta of cosmic ray induced muons can be measured from 20 to 2000 GeV/c. During the 1999 data taking period 5 billion muon events were recorded in the spectrometer. From April until mid Summer 2000 an additional 3 billion muon events have been recorded as well as 25 million air shower events. Here the first results on the muon momentum spectrum and charge ratio will be presented

Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease

BACKGROUND: Patients with atherosclerotic vascular disease remain at high risk for cardiovascular events despite effective statin-based treatment of low-density lipoprotein (LDL) cholesterol levels. The inhibition of cholesteryl ester transfer protein (CETP) by anacetrapib reduces LDL cholesterol levels and increases high-density lipoprotein (HDL) cholesterol levels. However, trials of other CETP inhibitors have shown neutral or adverse effects on cardiovascular outcomes. METHODS: We conducted a randomized, double-blind, placebo-controlled trial involving 30,449 adults with atherosclerotic vascular disease who were receiving intensive atorvastatin therapy and who had a mean LDL cholesterol level of 61 mg per deciliter (1.58 mmol per liter), a mean non-HDL cholesterol level of 92 mg per deciliter (2.38 mmol per liter), and a mean HDL cholesterol level of 40 mg per deciliter (1.03 mmol per liter). The patients were assigned to receive either 100 mg of anacetrapib once daily (15,225 patients) or matching placebo (15,224 patients). The primary outcome was the first major coronary event, a composite of coronary death, myocardial infarction, or coronary revascularization. RESULTS: During the median follow-up period of 4.1 years, the primary outcome occurred in significantly fewer patients in the anacetrapib group than in the placebo group (1640 of 15,225 patients [10.8%] vs. 1803 of 15,224 patients [11.8%]; rate ratio, 0.91; 95% confidence interval, 0.85 to 0.97; P=0.004). The relative difference in risk was similar across multiple prespecified subgroups. At the trial midpoint, the mean level of HDL cholesterol was higher by 43 mg per deciliter (1.12 mmol per liter) in the anacetrapib group than in the placebo group (a relative difference of 104%), and the mean level of non-HDL cholesterol was lower by 17 mg per deciliter (0.44 mmol per liter), a relative difference of -18%. There were no significant between-group differences in the risk of death, cancer, or other serious adverse events. CONCLUSIONS: Among patients with atherosclerotic vascular disease who were receiving intensive statin therapy, the use of anacetrapib resulted in a lower incidence of major coronary events than the use of placebo. (Funded by Merck and others; Current Controlled Trials number, ISRCTN48678192 ; ClinicalTrials.gov number, NCT01252953 ; and EudraCT number, 2010-023467-18 .)